Logo image of NKTR

NEKTAR THERAPEUTICS (NKTR) Stock Fundamental Analysis

NASDAQ:NKTR - Nasdaq - US6402681083 - Common Stock - Currency: USD

0.9322  -0.02 (-2.58%)

After market: 0.9401 +0.01 (+0.85%)

Fundamental Rating

3

NKTR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. NKTR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NKTR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NKTR had negative earnings in the past year.
In the past year NKTR has reported a negative cash flow from operations.
NKTR had negative earnings in each of the past 5 years.
In the past 5 years NKTR always reported negative operating cash flow.
NKTR Yearly Net Income VS EBIT VS OCF VS FCFNKTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M -400M 600M

1.2 Ratios

Looking at the Return On Assets, with a value of -54.65%, NKTR is doing worse than 64.86% of the companies in the same industry.
NKTR has a worse Return On Equity (-344.29%) than 77.30% of its industry peers.
Industry RankSector Rank
ROA -54.65%
ROE -344.29%
ROIC N/A
ROA(3y)-56.02%
ROA(5y)-43.84%
ROE(3y)-129.42%
ROE(5y)-92.18%
ROIC(3y)N/A
ROIC(5y)N/A
NKTR Yearly ROA, ROE, ROICNKTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

1.3 Margins

Looking at the Gross Margin, with a value of 67.80%, NKTR is in the better half of the industry, outperforming 71.35% of the companies in the same industry.
In the last couple of years the Gross Margin of NKTR has declined.
NKTR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.51%
GM growth 5Y-8.59%
NKTR Yearly Profit, Operating, Gross MarginsNKTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

6

2. Health

2.1 Basic Checks

NKTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
NKTR has more shares outstanding than it did 1 year ago.
NKTR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for NKTR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NKTR Yearly Shares OutstandingNKTR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
NKTR Yearly Total Debt VS Total AssetsNKTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

NKTR has an Altman-Z score of -16.27. This is a bad value and indicates that NKTR is not financially healthy and even has some risk of bankruptcy.
NKTR has a worse Altman-Z score (-16.27) than 82.70% of its industry peers.
NKTR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.27
ROIC/WACCN/A
WACC9.77%
NKTR Yearly LT Debt VS Equity VS FCFNKTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 4.24 indicates that NKTR has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.24, NKTR is doing good in the industry, outperforming 60.54% of the companies in the same industry.
NKTR has a Quick Ratio of 4.24. This indicates that NKTR is financially healthy and has no problem in meeting its short term obligations.
NKTR's Quick ratio of 4.24 is fine compared to the rest of the industry. NKTR outperforms 62.16% of its industry peers.
Industry RankSector Rank
Current Ratio 4.24
Quick Ratio 4.24
NKTR Yearly Current Assets VS Current LiabilitesNKTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.96% over the past year.
NKTR shows a small growth in Revenue. In the last year, the Revenue has grown by 5.60%.
Measured over the past years, NKTR shows a very negative growth in Revenue. The Revenue has been decreasing by -40.35% on average per year.
EPS 1Y (TTM)26.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)5.6%
Revenue growth 3Y-16.16%
Revenue growth 5Y-40.35%
Sales Q2Q%-0.08%

3.2 Future

The Earnings Per Share is expected to grow by 4.76% on average over the next years.
Based on estimates for the next years, NKTR will show a quite strong growth in Revenue. The Revenue will grow by 9.49% on average per year.
EPS Next Y25.48%
EPS Next 2Y10.62%
EPS Next 3Y8.76%
EPS Next 5Y4.76%
Revenue Next Year17.72%
Revenue Next 2Y0.63%
Revenue Next 3Y0.18%
Revenue Next 5Y9.49%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NKTR Yearly Revenue VS EstimatesNKTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
NKTR Yearly EPS VS EstimatesNKTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NKTR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NKTR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NKTR Price Earnings VS Forward Price EarningsNKTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NKTR Per share dataNKTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.62%
EPS Next 3Y8.76%

More info and screens

0

5. Dividend

5.1 Amount

NKTR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEKTAR THERAPEUTICS

NASDAQ:NKTR (2/21/2025, 8:00:01 PM)

After market: 0.9401 +0.01 (+0.85%)

0.9322

-0.02 (-2.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners74.29%
Inst Owner Change-6.69%
Ins Owners1.06%
Ins Owner Change10.11%
Market Cap171.95M
Analysts75.71
Price Target4.65 (398.82%)
Short Float %3.16%
Short Ratio2.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.04%
Min EPS beat(2)-20.38%
Max EPS beat(2)16.31%
EPS beat(4)2
Avg EPS beat(4)-0.91%
Min EPS beat(4)-20.38%
Max EPS beat(4)16.31%
EPS beat(8)4
Avg EPS beat(8)-1.06%
EPS beat(12)8
Avg EPS beat(12)5.69%
EPS beat(16)12
Avg EPS beat(16)6.57%
Revenue beat(2)2
Avg Revenue beat(2)30.32%
Min Revenue beat(2)29.38%
Max Revenue beat(2)31.25%
Revenue beat(4)4
Avg Revenue beat(4)32.15%
Min Revenue beat(4)29.38%
Max Revenue beat(4)38.28%
Revenue beat(8)6
Avg Revenue beat(8)16.99%
Revenue beat(12)7
Avg Revenue beat(12)10.68%
Revenue beat(16)8
Avg Revenue beat(16)5.33%
PT rev (1m)-2.98%
PT rev (3m)72.08%
EPS NQ rev (1m)-3.67%
EPS NQ rev (3m)16.88%
EPS NY rev (1m)-1.19%
EPS NY rev (3m)6.9%
Revenue NQ rev (1m)-0.15%
Revenue NQ rev (3m)48.68%
Revenue NY rev (1m)-0.62%
Revenue NY rev (3m)17.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.85
P/FCF N/A
P/OCF N/A
P/B 3.52
P/tB 3.52
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0.5
BVpS0.27
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.65%
ROE -344.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.8%
FCFM N/A
ROA(3y)-56.02%
ROA(5y)-43.84%
ROE(3y)-129.42%
ROE(5y)-92.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.51%
GM growth 5Y-8.59%
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.45%
Cap/Sales 1.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.24
Quick Ratio 4.24
Altman-Z -16.27
F-Score4
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)53.77%
Cap/Depr(5y)82.39%
Cap/Sales(3y)7.29%
Cap/Sales(5y)9.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y25.48%
EPS Next 2Y10.62%
EPS Next 3Y8.76%
EPS Next 5Y4.76%
Revenue 1Y (TTM)5.6%
Revenue growth 3Y-16.16%
Revenue growth 5Y-40.35%
Sales Q2Q%-0.08%
Revenue Next Year17.72%
Revenue Next 2Y0.63%
Revenue Next 3Y0.18%
Revenue Next 5Y9.49%
EBIT growth 1Y6.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.84%
EBIT Next 3Y10.87%
EBIT Next 5YN/A
FCF growth 1Y56.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.64%
OCF growth 3YN/A
OCF growth 5YN/A